Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Assembly Biosciences
(NQ:
ASMB
)
14.72
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Assembly Biosciences
< Previous
1
2
3
4
Next >
12 Health Care Stocks Moving In Wednesday's After-Market Session
October 25, 2023
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
October 18, 2023
Via
Benzinga
Crude Oil Moves Lower; Bank of America Profit Beats Expectations
October 17, 2023
U.S. stocks traded mostly lower toward the end of trading, with the Nasdaq Composite falling around 50 points on Tuesday. The Dow traded down 0.09% to 33,954.39 while the NASDAQ fell 0.37% to...
Via
Benzinga
Topics
Stocks
Exposures
Fossil Fuels
US Equities
Why ServisFirst Bancshares Shares Are Trading Lower By 6%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
October 17, 2023
Gainers SciSparc Ltd. (NASDAQ: SPRC) shares climbed 146.2% to $6.97. Aegis Capital Corp. acted as exclusive placement agent on a $5.0 million private placement for SciSparc.
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
October 17, 2023
Via
Benzinga
Dow Surges 100 Points; Goldman Sachs Posts Upbeat Earnings
October 17, 2023
U.S. stocks traded mostly higher midway through trading, with the Dow Jones falling gaining around 100 points on Tuesday. The Dow traded up 0.31% to 34,090.15 while the NASDAQ fell 0.05% to 13,560.52....
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why Are Stocks Down Today?
October 17, 2023
Stocks are down today, and investors wondering why are in the right place as we have all the details they need to know about on Tuesday!
Via
InvestorPlace
Why Is Assembly Biosciences (ASMB) Stock Up 92% Today?
October 17, 2023
Assembly Biosciences stock is taking off with heavy trading of ASMB shares after the company announced a new collaboration agreement!
Via
InvestorPlace
Nasdaq Down Over 1%; US Retail Sales Top Expectations
October 17, 2023
U.S. stocks traded lower this morning, with the Nasdaq Composite falling more than 1% on Tuesday. Following the market opening Tuesday, the Dow traded down 0.11% to 33,947.98 while the NASDAQ fell...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Hepatitis-Focused Assembly Biosciences Stock Trading Over 100% Higher: Here's Why
October 17, 2023
Gilead Sciences Inc (NASDAQ: GILD) and Assembly Biosciences Inc (NASDAQ: ASMB) have entered into a 12-year partnership.
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
October 17, 2023
Via
Benzinga
Gilead and Assembly Biosciences Establish Partnership to Develop Next-Generation Therapeutics for Serious Viral Diseases
October 17, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Assembly Biosciences to Present New Data at AASLD The Liver Meeting®
October 11, 2023
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Assembly Biosciences Nominates Development Candidate ABI-6250, an Orally Bioavailable HDV Entry Inhibitor
October 02, 2023
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Assembly Biosciences to Highlight Pipeline Progress in HBV and HDV at the 2023 International HBV Meeting
September 19, 2023
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Assembly Biosciences Reports Second Quarter 2023 Financial Results and Recent Updates
August 09, 2023
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Assembly Biosciences Presents New Data Highlighting Herpes Simplex Virus Development Candidate ABI-5366 at the 47th Annual International Herpesvirus Workshop
July 17, 2023
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
July 14, 2023
Via
Benzinga
Assembly Biosciences Presents New Data Highlighting Entry Inhibitor and Core Inhibitor Programs at EASL’s International Liver Congress™ 2023
June 21, 2023
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL International Liver Congress™ 2023
June 07, 2023
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Assembly Biosciences to Present During the 2023 Jefferies Healthcare Conference
May 23, 2023
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Assembly Biosciences Reports First Quarter 2023 Financial Results and Recent Highlights
May 04, 2023
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Assembly Biosciences Announces Additional Promising Data from Phase 1a Clinical Trial Evaluating Highly Potent Next-Generation Core Inhibitor Candidate ABI-4334 and Provides Pipeline Update
April 18, 2023
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
April 03, 2023
Via
Benzinga
Assembly Biosciences Provides Update on its Core Inhibitor Pipeline, Reports Fourth Quarter and Year End 2022 Financial Results and Recent Highlights
March 22, 2023
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Assembly Biosciences Nominates First Herpesvirus Development Candidate ABI-5366, a Long-Acting HSV-2 Helicase Inhibitor Targeting High-Recurrence Genital Herpes
February 15, 2023
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Assembly Biosciences Shares Gain After Promising Early Cut Data From HBV Infection Programs
December 19, 2022
Assembly Biosciences Inc (NASDAQ: ASMB) announced interim efficacy, safety, and pharmacokinetic (PK) results from a Phase 1b study of ABI-H3733 (3733) and a Phase 1a study of ABI-4334 (4334).
Via
Benzinga
Assembly Biosciences Announces Promising Interim Results from Two Clinical Trials Evaluating Highly Potent Next-Generation Core Inhibitor Candidates ABI-H3733 and ABI-4334
December 19, 2022
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Assembly Biosciences Doses First Subject in Phase 1a Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetic Profile of Investigational Next Generation Core Inhibitor ABI-4334
November 14, 2022
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Assembly Biosciences Reports Third Quarter 2022 Financial Results and Recent Highlights and Announces Upcoming Conference Participation
November 08, 2022
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.